Farnesyl Transferase Inhibitors Cause Enhanced Mitotic Sensitivity to Taxol and Epothilones

An important class of cellular proteins, which includes members of the p21ras family, undergoes posttranslational farnesylation, a modification required for their partition to membranes. Specific farnesyl transferase inhibitors (FTIs) have been developed that selectively inhibit the processing of th...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 95; no. 4; pp. 1369 - 1374
Main Authors Moasser, Mark M., Sepp-Lorenzino, Laura, Kohl, Nancy E., Oliff, Allen, Balog, Aaron, Su, Dai-Shi, Danishefsky, Samuel J., Rosen, Neal
Format Journal Article
LanguageEnglish
Published United States National Academy of Sciences of the United States of America 17.02.1998
National Acad Sciences
National Academy of Sciences
The National Academy of Sciences
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:An important class of cellular proteins, which includes members of the p21ras family, undergoes posttranslational farnesylation, a modification required for their partition to membranes. Specific farnesyl transferase inhibitors (FTIs) have been developed that selectively inhibit the processing of these proteins. FTIs have been shown to be potent inhibitors of tumor cell growth in cell culture and in murine models and at doses that cause little toxicity to the animal. These data suggest that these drugs might be useful therapeutic agents. We now report that, when FTI is combined with some cytotoxic antineoplastic drugs, the effects on tumor cells are additive. No interference is noted. Furthermore, FTI and agents that prevent microtubule depolymerization, such as taxol or epothilones, act synergistically to inhibit cell growth. FTI causes increased sensitivity to induction of metaphase block by these agents, suggesting that a farnesylated protein may regulate the mitotic check point. The findings imply that FTI may be a useful agent for the treatment of tumors with wild-type ras that are sensitive to taxanes.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
Contributed by Samuel J. Danishefsky
To whom reprint requests should be addressed. e-mail: rosenn@mskcc.org.
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.95.4.1369